Journal article
In silico repositioning of approved drugs for rare and neglected diseases
Drug discovery today, Vol.16(7), pp.298-310
2011
DOI: 10.1016/j.drudis.2011.02.016
PMID: 21376136
Abstract
One approach to speed up drug discovery is to examine new uses for existing approved drugs, so-called ‘drug repositioning’ or ‘drug repurposing’, which has become increasingly popular in recent years. Analysis of the literature reveals many examples of US Food and Drug Administration-approved drugs that are active against multiple targets (also termed promiscuity) that can also be used to therapeutic advantage for repositioning for other neglected and rare diseases. Using proof-of-principle examples, we suggest here that with current
in silico technologies and databases of the structures and biological activities of chemical compounds (drugs) and related data, as well as close integration with
in vitro screening data, improved opportunities for drug repurposing will emerge for neglected or rare/orphan diseases.
Details
- Title: Subtitle
- In silico repositioning of approved drugs for rare and neglected diseases
- Creators
- Sean Ekins - Collaborations in Chemistry, 601 Runnymede Avenue, Jenkintown, PA 19046, USAAntony J Williams - Royal Society of Chemistry, 904 Tamaras Circle, Wake Forest, NC 27587, USAMatthew D Krasowski - Department of Pathology, University of Iowa Hospitals and Clinics, Iowa City, IA 52242, USAJoel S Freundlich - Department of Biochemistry and Biophysics, Texas A&M University, College Station, TX 77843, USA
- Resource Type
- Journal article
- Publication Details
- Drug discovery today, Vol.16(7), pp.298-310
- DOI
- 10.1016/j.drudis.2011.02.016
- PMID
- 21376136
- NLM abbreviation
- Drug Discov Today
- ISSN
- 1359-6446
- eISSN
- 1878-5832
- Publisher
- Elsevier Ltd
- Language
- English
- Date published
- 2011
- Academic Unit
- Pathology
- Record Identifier
- 9984047976102771
Metrics
6 Record Views